2024 AGENDA

NETWORKING BREAKFAST:
BUILD COMMUNITY CONTACTS

OPENING COMMENTS FROM YOUR HOST

PANEL DISCUSSION: RARE DISEASES

Reflections on the Rare Disease Drug Strategy: Lessons Learned & A Way Forward

Industry Expert: RWE FOR HEALTH TECHNOLOGY ASSESSMENTS

Enhancing the Quality and Utility of RWE to Improve Patient Care and Optimize Market Access Success

PANEL DISCUSSION: THE PRIVATE PAYER MARKET

Discover What Changes Are Taking Place in the Private Payer Market that will Impact Your Organization

NETWORKING BREAK: SOURCE MARKET ACCESS EXPERTISE

ROUNDTABLES: DISCOVER THOUGHT-PROVOKING IDEAS

PANEL DISCUSSION: PREFERRED PHARMACY NETWORKS (PPNs)

Benefit from an Analysis of the Impact of PPNs on Patients, Drug Costs and Efficient Market Access

NETWORKING LUNCH: DELVE INTO INDUSTRY CONVERSATIONS

PANEL DISCUSSION: BEYOND THE TRANSITION TO BIOSIMILARS

Assess the Impact of Transitioning to Biosimilars for Patients, Payers and Manufacturer

PANEL DISCUSSION: PATIENT SUPPORT PROGRAMS

Expand your Understanding of the Impact PSPs have on Patient Access, Pricing and Healthcare Sustainability

EXHIBITOR LOUNGE: ATTEND VENDOR DEMOS & CONSULT INDUSTRY EXPERTS

UNLOCKING INNOVATION WITH OBA’s

Is Canada Stalling While Other HTA Countries Speed Ahead?

PANEL DISCUSSION: ADDRESSING DRUG SHORTAGES

Increasing the Resiliency of our Drug Supply and Supply Chain to Prevent and Mitigate Shortages

CLOSING COMMENTS FROM YOUR HOST

CONFERENCE CONCLUDES